Genentech Manufacturing Deal With Lonza Provides For Future Biologic Expansion
This article was originally published in The Pink Sheet Daily
Genentech plans to sell its 40,000-liter facility in Spain to Lonza, while in turn gaining the option to buy Lonza’s 80,000-liter facility in Singapore.
You may also be interested in...
Biogen Tysabri Facility Will Shift To Avastin Production Under New Owner
Genentech agreed to pay Biogen $408.1 mil. for its southern California Tysabri facility to add capacity for Avastin. The facility was undergoing validation; Biogen expected to begin selling the multiple sclerosis therapy out of the facility by 2006.
Roche Pharma CEO Graham On Growth Prospects, Policy Pressures, Alzheimer’s And More
“I don’t think anybody can afford to not be in the Alzheimer’s race,” Graham said in one of her first public appearances since becoming CEO of Roche pharmaceuticals.
Commercial Fate Of Sarepta’s DMD Gene Therapy Remains Tied To EMBARK
The company guided investors to expect a narrow initial label under a US FDA accelerated approval for SRP-9001, with expansion possible based on EMBARK.